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ABSTRACT
Objectives: Estrogen receptors are believed to play a significant role in the pathogenesis of 
prostate carcinoma (PCa). The aim of this study is to evaluate the expression of ER-α and ER-β 
in human benign and malignant prostatic tissue.
Patients and Methods: The archival materials of 100 prostatic specimens (65 PCa, 35 BPH) 
were collected from the Department of Pathology, King Abdul-Aziz University Hospital, Jeddah, 
Saudi Arabia. Seven PCa cases contained foci of high-grade prostate intraepithelial neoplasia 
(HGPIN). Immunohistochemistry was used to test the protein expression of ER-α and ER-β 
utilizing monoclonal mouse antihuman antibodies.
Results: Among the 65 cases of PCa, ER-α was expressed in 3 cases (4.6%) in epithelial cells and 
4 cases (6.1%) in stromal cells. ER-α was not expressed in any of the HGPIN foci. Additionally, 
ER-α was not expressed in either luminal or basal cells in any of the 35 BPH cases. However it 
was expressed in 4 cases (11.4%) in stromal cells of BPH. In PCa, ER-β was expressed in 61 cases 
(93.8%) and 35 cases (53.8%) in the epithelial and stromal cells respectively. ER-β was expressed 
only in 2 cases (28.5%) out of 7 HGPIN foci. It was expressed in 33 cases (94.3%) of epithelial 
and stromal cells of BPH. 
Conclusion: The majority of PCa and BPH exhibited nuclear immunoreactivity for ER-β in both 
tumor and stromal cells and they are usually negative for ER-α. There is probably partial loss of 
ER-β in HGPIN. ER-β may have a role in the process of prostatic hyperplasia and malignancy.
Key Words: ER-α, ER-β, prostate, hyperplasia, premalignant, cancer, immunohistochemistry             
Corresponding Author: Dr. Jaudah Al-Maghrabi, Department of Pathology, Faculty 
of Medicine King Abdul-Aziz University Hospital, P. O. BOX 80205, Jeddah 21589, 
Saudi Arabia, Email: jalmaghrabi@hotmail.com
Article Info : Date received: 5/7/2010                           Date accepted (after revision): 11/8/2010 
INTRODUCTION                                                    
Prostate carcinoma (PCa) is a large 
global health problem. It is the second most 
commonly diagnosed cancer in men and is 
the second leading cause of cancer-related 
death in the United States1-4. Several studies 
have focused on the association between 
androgens and PCa risk, postulating that 
androgens are needed for prostate growth 
and differentiation5-7. Nevertheless, there is 
a growing body of evidence to suggest that 
estrogen signaling also plays a significant 
role in normal and abnormal growth of the 
prostate gland8-11. Estrogens directly target 
prostate tissue by specific estrogen receptors 
(ER). The human prostate is equipped with 
a dual system of ERs (ER-α and ER-β) 
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Immunohistochemical examination and 
interpretation
The specimens were previously fixed 
in 10% formalin solution and prepared 
for the immunohistochemical procedure 
using the avidin-biotin immuno-enzymatic 
technique (ABT). The principal steps are 
as follows: selected blocks were cut into 5 
micron sections, deparaffinized in xylene, 
rehydrated in graded alcohol and rinsed in 
Tris-buffered saline (TBS). Antigen-retrieval 
was done using water bath microwave. 
The sections were incubated in 5% normal 
rabbit serum and incubated with monoclonal 
mouse antihuman antibodies for ER-α 
(dilution 1: 35; clone 1D5, Dako) and 
ER-β (dilution 1: 35; clone PPG5/10; 
Dako). The slides were visualized using 
3, 3’-diaminobenzidine (DAB). Meyer’s 
hematoxylin was used as counter stain. 
Positive and negative controls were used with 
each run of immunoassay. Positive control 
sections were obtained from mammary tissue 
known to be positive for the antibodies. 
Primary antibodies were omitted for negative 
controls. The case was only considered 
positive when both negative and positive 
controls were working, which avoids any 
false positive staining. After completion 
of the immunohistochemical staining, the 
cases were examined microscopically for 
the localization and intensity of the selected 
antibody. The degree of immunoreactivity 
in the targeted cells was evaluated. Positive 
immunohistochemical staining was defined 
as unequivocal nuclear staining of at least 
10% of the cells. The intensity of staining 
was determined and scored in an ascending 
1 to 3 scale17.
Statistical analysis
Statistical analysis was performed with 
Fisher’s exact test using GraphPad InStat, 
Version 4 (GraphPad Software Inc, La 
Jolla, CA, USA). Statistical significance 
was determined as p<0.05.
that undergoes profound remodeling 
during prostate cancer development and 
progression12-14. The evidence on the role of 
estrogens and ER in prostate carcinogenesis 
is largely obtained from experimental data 
reported in animal models15. In rat models, 
it was clear that estrogens are required for a 
maximal carcinogenic response to androgens. 
The question arises whether the carcinogenic 
effects of estrogens demonstrated in animal 
prostate cancer models are applicable to 
the biology of the human prostate, as few 
studies have addressed this issue in humans16. 
Additionally, the complex intraprostatic 
interactions of estrogens and ER as well 
as their combined effect remain to be 
ascertained. In this study we examined the 
expression of ER-α and ER-β in human PCa 
as well as benign prostatic hyperplasia (BPH) 
specimens, using immunohistochemistry 
techniques to localize ER expression in 
epithelial (luminal and basal) as well as 
stromal cells.
MATERIALS AND METHODS                   
Setting and specimens: The study was 
conducted in the Departments of Pathology 
and Urology at King Abdul-Aziz University 
Hospital, Jeddah, Saudi Arabia. The archived 
prostatic specimens (100) of 65 consecutive 
patients with PCa and 35 patients with BPH 
obtained from 2003 to 2008 were selected for 
the study. BPH was pathologically diagnosed 
as glandular and/or fibromuscular hyperplasia 
in transurethral resection of the prostate 
(TURP) or open prostatectomy specimens or 
transrectal ultrasound (TRUS) guided prostate 
biopsies. The study involved 40 TRUS 
guided biopsies, 45 TURP specimens and 15 
open surgical prostatectomy specimens. The 
indications for biopsy were elevated serum 
PSA levels, abnormal findings on digital 
rectal examination, or both. Biopsy cores 
were obtained according to the standard 
sextant technique. The indications for surgical 
intervention in BPH patients included failed 
medical therapy with alpha-blockers and/or 
5-alpha reductase inhibitors, refractory or 
repeated episodes of acute urinary retention 
(AUR), recurrent urinary tract infections 
and hematuria.
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RESULTS                                                            
The histopathology findings in the 100 
specimens (65 PCa and 35 BPH) are shown 
in Table 1. Foci of HGPIN were seen in 7 
cases (10.8%) of PCa specimens (Fig. 1).
ER-α expression in PCa specimens
Out of the 65 PCa specimens, only 3 
(4.6%) revealed nuclear immunoreactivity 
(Fig. 2), while 62 (95.4%) were negative 
for nuclear ER-α expression (Fig. 2 and 
Table 2). Two of the ER-α positive case 
were Gleason score 7 and one score 8. Four 
PCa specimens (6.2%) exhibited stromal 
cell nuclear immunoreactivity. Seven cases 
(10.8%) demonstrated weak non-specific 
cytoplasmic staining for ER-α without any 
nuclear positivity. The 2 specimens of SCC as 
well as the 7 foci of HGPIN were all negative 
for nuclear ER-α immunoexpression. 
ER-α expression in BPH specimens
All BPH specimens were negative for 
ER-α immunoexpression in the epithelial cells 
(Fig. 2) although 4 BPH specimens (11.4%) 
showed nuclear stromal cell reactivity for 
ER-α (Table 2).
ER-β expression in PCa specimens
Among PCa, 61 (93.8%) of specimens 
showed diffuse ER-β nuclear immunoreactiv-
ity with variable degrees of intensity in can-
cer cells (Fig. 3). Among them 26 specimens 
(42.6%) showed strong ER-β immunoexpres-
sion with score (3+) reactivity, 24 (39.3%) 
were score (2+) and 11 (18.1%) showed 
score (1+). Two of the specimens labeled as 
negative showed only focal nuclear staining 
for ER-β (less than 10% of the cells) and the 
other 2 specimens lacked any nuclear immu-
noexpression. The ER-β negative cases were 
Gleason score 6 (2 cases) and 7 (2 cases). 
Similarly, the two specimens of SCC showed 
strong positive nuclear immunoreactivity for 
ER-β. Thirty five (53.8%) of PCa specimens 
showed stromal cell immunoexpression for 
ER-β (Table 3). ER-β was expressed only in 2 
(28.5%) of 7 PIN foci. No cytoplasmic stain-
ing was seen in any of the specimens.
ER-β expression in BPH specimens
Thirty three of 35 BPH specimens dem-
onstrated positive nuclear immunostaining in 
the secretory cell layers. As shown in Table 
3, 18 specimens (51.4%) exhibited diffuse 
ER-β nuclear immunoreactivity, 15 (42.9%) 
showed focal ER-β nuclear immunopositiv-
ity, while the remaining 2 (5.7%) lacked any 
nuclear immunoexpression (Fig. 3). Among 
the 33 positive nuclear immunostaining 
BPH specimens, 11 (33.3%) revealed score 
(3+), 19 (57.6%) showed score (2+) and 3 
(9.1%) were score (1+). Basal cell layer im-
munoexpression for ER-β was detected in 25 
(71.4%) BPH specimens. All BPH specimens 
that revealed positive epithelial nuclear im-
munoreactivity also revealed stromal cell 
immunopositivity. The specimens which 
lacked epithelial nuclear immunoreactiv-
ity lacked stromal cell reactivity as well. 
No cytoplasmic staining was seen in any of 
the specimen.
Fig. 1-A: Well differentiated prostate carcinoma 
(H&E X200)
Fig. 1-B: A focus of high-grade prostate intraepithelial 
neoplasia (HGPIN) (H&E X200)
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Fig. 2-A: Prostate cancer with immuno-negativity for ER-α in 
both tumor and stromal cells (DAB X 400)
Fig. 2-B: Prostate cancer with positive immunoreactivity 
for ER-α in tumor cells (upper left corner) and negative 
immunostaining in stromal cells (DAB X 400)
Fig. 2-C: Benign prostatic hyperplasia with negative 
immunostaining for ER-α in both epithelial and stromal 
cells (DAB X200)
Fig. 2-D: Benign prostatic hyperplasia with negative nuclear 
immunostaining for ER-α in both glandular epithelium and 
stromal cells (DAB X200)
Fig. 3-A: Prostate cancer with strong and diffuse positive 
immunoreactivity for ER-β in tumor as well as stromal 
cells (DAB X100)
Fig. 3-B: Prostate cancer with positive immunostaining for 
ER-β in tumor (DAB X100)
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DISCUSSION                                                             
Elucidation of the mechanisms of action 
of estrogens in prostatic carcinogenesis will 
likely spur novel strategies in prostate can-
cer prevention and treatment. Probably, there 
will be a significant potential for the use of 
ER-α and ER-β modulators to prevent pros-
tate cancer and delay disease progression18. It 
was reported that ER-β may play a significant 
role in prostate cell differentiation and pro-
liferation and may modulate both the initial 
phases of prostate carcinogenesis and andro-
gen-independent tumor growth. It remains 
to be etablished whether ER-β enhances or 
suppresses prostate cancer development and/
or progression19. For prostatic cancer cell 
lines, LNCap expressed the mRNA of both 
Fig. 3-C: Prostate cancer with negative immunoreactivity for 
ER-β in tumor and stromal cells (DAB X200)
Fig. 3-D: Benign prostatic hyperplasia with positive 
immunostaining for ER-β in luminal, basal and stromal cells 
(upper right corner) (DAB X200)
Fig. 3-E: Prostatic small cell carcinoma with strong and 
diffuse positivity for ER-β in tumor cells (DABX200)
Fig. 3-F: High-grade prostatic intra-epithelial neoplasia 
(HGPIN) with positive nuclear immunostaining for ER-β in 
the dysplastic cells (DAB X200)
receptors, but DU-145 and PC-3 only ex-
pressed ER-β mRNA20,21. Although ER-α and 
ER-β have similar ligand-binding domains 
and both bind estrogen, there is evidence 
that ER-α and ER-β demonstrate distinct and 
sometimes opposing transcriptional activi-
ties22-23. Also, upregulation of ER-β expres-
sion by certain drugs such as phytoestrogens 
and isoflavones has been found to be able to 
transform prostate cancer cells into a less ma-
lignant phenotype which can add more insi-
ghts into the role of ER-β in prostate cancer 
management24. Ellem and Risbridger25 sug-
gested that ER-β appears to mediate its bene-
ficial effects by preventing hyperplasia, in-
flammation and carcinogenesis. Additionally, 
ER-β may protect normal prostate epithelia 
from undergoing aberrant cell proliferation 
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and may have a role in enhancing survival of 
PCa cells14,18,26-29. In another study, Zhu et al 
demonstrated evidence of repression of ER-β 
in local PCa and re-expression of the gene 
within metastasis30. It has been suggested that 
there is a significant role of prostatic inflam-
mation in the pathogenesis of PCa. However, 
the link between estrogen, inflammation and 
PCa requires further investigation31-33.
Our study has confirmed previous re-
ports31-36 that ER-α is not usually seen in the 
tumor cells or epithelial cells of BPH and can 
be seen rarely in the stromal cells. There was 
no statistically significant difference between 
PCa and BPH regarding the expression of 
ER-α (p = 0.54). Similarly, our observation is 
in agreement with  those mentioned by Hor-
vath et al18 who reported that none of the 39 
radical prostatectomy specimens examined 
showed epithelial staining for ER-α, but 16 
cases had stromal staining of ≥5% positive 
nuclei. In our study there was no relationship 
between the type of prostatic specimen exa-
mined and the immunopositivity for ER-α 
expression. There was also no relationship 
between the combined Gleason score and the 
degree of ER-α expression. 
Most previous studies failed to show si-
gnificant levels of ER-α immunostaining 
in the epithelial components, while immu-
nostaining when found was confined to the 
stromal tissue34,37. However, a few previous 
studies12,14,38 found positive ER-α immu-
nostaining in the epithelia. They described 
this as immunolocalization within the basal 
cell layer. Yet, this staining was universally 
weak. ER-α was down regulated in PCa hor-
mone refractory tumors39,40. Additionally, 
some authors reported that the level of ER-α 
expression and methylation was inversely 
correlated with the pathological grades of 
PCa34,41. Our findings are also in contrast with 
those reported by Bonkhoff and co-workers12 
who found immunostaining of ER-α in high-
grade dysplasia and grade 4-5 PCa. Walton et 
al38 performed a study on pure populations of 
benign and malignant prostatic epithelial cells 
after alteration of >99% of the stromal cells. 
They reported that median ER-α expression 
was 9.4 times more common than ER-β ex-
pression. This discrepancy may be due to the 
use of RT-PCR technique. Some authors9,42 
reported that higher levels of ER-α was ob-
served in Hispanics and Asian men than in 
Caucasian and African-American men. In the 
Japanese population polymorphism in codon 
10 ER-α was found to be associated with PCa 
43.
In our study, all 7 foci of HGPIN were 
negative for ER-α immunoexpression. Leav 
et al14 reported that ER-α expression was 
limited only to a small subset of dysplastic 
lesions. Bonkhoff et al suggested that ER-α 
in the human prostate acts as an oncogene, 
which is overexpressed during malignant 
transformation of the prostatic epithelium12. 
The complete absence of ER-α in basal and 
luminal cells in our study is not supportive of 
this conclusion.
Regarding the expression of ER-β in 
PCa, this study revealed that 93.8% of the 
cases were diffusely immunoreactive for 
ER-β, 3.1% were focally positive, while 
the remaining 3.1% were negative for ER-β 
immunoexpression. The majority of studied 
PCa specimens exhibited moderate to strong 
positive nuclear ER-β immunoreactivity. 
Additionally, 35 cases (53.8%) of PCa 
showed stromal cell immunostaining for 
ER-β. There was no statistically significant 
difference between PCa and BPH regarding 
the expression of ER-β (p = 1.00). Similar 
to ER-α, ER-β immunostaining was not 
affected by the type of prostatic specimen 
or by the Gleason score. We noticed also 
that ER-β immunoexpression was seen in 
2 (28.5%) of the 7 HGPIN foci. About the 
immunoexpression of ER-β in BPH, this study 
revealed that 94.3% exhibited either diffuse or 
focal nuclear immunostaining in the secretory 
cell layers. However, immunoexpression of 
ER-β in the basal cell layer was detected in 
71.4% of the cases. Additionally, stromal 
cell immunostaining was seen in all BPH 
specimens that revealed positive epithelial 
nuclear immunoreactivity (94.3%). 
The results on ER-β expression in PCa 
are even more controversial and conflicting. 
Multiple previous publications reported 
complete loss of ER-β immunostaining in 
PCa18,30,44-46.  Hormone-naive PCa was reported 
to retain high levels of ER-β expression even 
in lymph node and bone metastasis 13. Gabal et 
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al   reported ER-β nuclear immunoreactivity in 
90% of the studied BPH cases. They showed 
that 53% of PIN cases were negative for ER-β 
expression and 82.8% of the studied PCa 
cases were negative47. However, a study done 
by Stettner et al24 reported no change in the 
expression of ER-β in PCa. On the other hand, 
Walton et al38 used quantitative RT-PCR 
technique and reported 4.5 fold increases in 
the expression of ER-β in PCa specimens 
compared with BPH. Additionally, they 
found a significant positive correlation 
between ER-β expression and androgen 
receptor-dependent PSA PCa. Torlakovic et 
al reported that ER-β was expressed in 93% 
of PCa and was positively associated with 
primary Gleason grade48. They suggested that 
ER-β, as detected by PPG5/10 antibody, may 
have a role in the process of dedifferentiation 
of PCa, with higher levels present in less 
differentiated tumors48.
Our study, did not show any correlation 
between tumor Gleason score and ER-β 
expression. Lai et al49 reported that ER-β was 
expressed in all 33 studied cases of osseous 
metastasis and in all 27 cases of non-osseous 
metastasis from PCa. They suggested that the 
use of selective estrogen modulators may be 
an effective method of treating advanced PCa. 
They speculated that the intense staining of 
ER-β in metastases may be due to changes of 
the methylation pattern of ER-β promoter in 
metastasic versus primary PCa. In our study 
we noticed a loss of ER-β immunoexpression 
in HGPIN. As the chemopreventive role of 
phytoestrogens depends on the presence and 
function of ER-β, it can be speculated that the 
dietary intake of phytoestrogens is beneficial 
in those patients with either no HGPIN or 
with HGPIN retaining high levels of ER-β 
expression16. 
The variation between different studies 
regarding ER-β status in PCa may due to the 
different techniques used, duration of fixation, 
fixative used, prolonged exposure of slides to 
room air or even using different cut-off values 
for positivity in the same technique. For 
example, some of the studies defined positive 
expression for ER as nuclear staining in 
>50% by immunohistochemistry techniques, 
while others used lower cut-off values. The 
problem with PCR techniques is the purity 
of the material and the inclusion of stromal 
and epithelial cells in the specimens. In this 
study we utilized the immunohistochemistry 
technique which is a powerful and generally 
accepted tool for assessment of ER status 
in breast cancer. We also used the generally 
accepted cut-off value for positivity, which 
is 10% of the cells with clear nuclear 
staining50, 51.
CONCLUSIONS                                                             
In this study, the majority of PCa and 
BPH specimens were negative for nuclear 
immunostaining for ER-α in both tumor and 
stromal cells. ER-α was negative in both 
luminal and basal cells in the BPH cases. 
The majority of PCa and BPH specimens 
exhibited nuclear immunoreactivity for 
ER-β in both tumor and stromal cells. 
Also, ER-β was positive in the majority of 
luminal and basal cells in BPH. Although 
the number of HGPIN cases was small in 
this study, the results suggested partial loss 
of ER-β in HGPIN. Both ER-α and ER-β 
immunopositivity was not affected by the 
type of prostatic specimen or the grade of Pca. 
The predominance of ER-β in the prostate 
may offer new opportunities for designing 
therapies or intervention strategies based on 
understanding the biology of ER subtypes. 
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